人福医药：玉蚕颗粒进入II 期临床试验研究

Core Viewpoint - The announcement by Renfu Pharmaceutical regarding the initiation of a Phase II clinical trial for Yucan Granules aimed at treating diabetic kidney disease with significant albuminuria highlights the company's commitment to advancing its research and development efforts in the pharmaceutical sector [1] Company Summary - Renfu Pharmaceutical's wholly-owned subsidiary, Wuhan Renfu Innovative Drug Research Center, has registered a Phase II clinical trial for Yucan Granules on the National Medical Products Administration's platform [1] - The trial is designed as a multicenter, randomized, double-blind, placebo-controlled study [1] - The primary objective of the trial is to evaluate the efficacy and safety of Yucan Granules in treating diabetic kidney disease with significant albuminuria and to explore dosage for future Phase III clinical research [1]